07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Aganirsen: Phase III data

Data from 69 patients with keratitis-related progressive corneal neovascularization in the intent-to-treat (ITT) population of the double-blind, European Phase III I-CAN trial showed that twice-daily 86 µg aganirsen eye drops per eye missed the primary...
02:05 , May 13, 2014 |  BC Extra  |  Clinical News

Gene Signal publishes mixed data for aganirsen

Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101 ) eye drops from Gene Signal International S.A. (Lausanne, Switzerland) missed the primary endpoint of improving absolute mean visual acuity value from baseline to day...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

Aganirsen: Phase IIa data

A double-blind Phase IIa trial in 12 patients with psoriasis showed that once-daily 0.86 and 1.72 mg/g topical aganirsen each met the primary endpoint of reducing psoriatic lesion size from baseline to week 6 vs....
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Insulin receptor substrate 1 (IRS1); phosphatidylinositol 3-kinase catalytic subunit a-polypeptide (PIK3CA; p110a); phosphoinositide 3-kinase-a (PI3Ka) Cell culture and mouse studies...
07:00 , Apr 1, 2013 |  BioCentury  |  Strategy

Shire sees opportunity

With two ophthalmics deals in as many weeks, Shire plc has revealed the next specialty area in which it wants a foothold. The company believes the small size of the ophthalmic practitioner population - about...
07:00 , Sep 21, 2009 |  BioCentury  |  Product Development

Seeing the Signal

For most ophthalmic diseases in which neovascularization is an issue, VEGF has become the target of choice. Gene Signal S.A.S. is going after a more selective angiogenesis target - IRS1 - that it says has...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Antisense oligonucleotide: Interim Phase II data

In a double-blind, vehicle-controlled Phase II trial in 40 patients who did not respond to conventional therapy, 86 µg/day GS-101 met the primary endpoint of inhibition and regression of corneal neovascularization vs. placebo. Specifically, the...
01:33 , Sep 2, 2009 |  BC Extra  |  Clinical News

Gene Signal reports GS-101 data

Gene Signal S.A.S. (Lausanne, Switzerland) said interim data showed 86 ug/day of topical GS-101 met the primary endpoint vs. placebo in a Phase II trial to treat corneal neovascularization. Specifically, 86 ug/day of the antisense...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Antisense oligonucleotide: Phase I data

Data from 14 healthy volunteers in an open-label, dose-escalation Phase I trial showed that 43-430 ug/day topical GS-101 administered to 1 eye thrice daily for 14 days was well tolerated compared with the untreated eye....